Argatroban Emergency Availability

In the event your customer needs Argatroban and it is not currently available at the hospital's primary or secondary wholesaler, take the following steps to arrange an emergency drop shipment of Argatroban directly to the hospital pharmacy.

During normal business hours (8:00 a.m. to 5:00 p.m. Eastern Time), contact GSK Customer Satisfaction at 1-800-877-1158.

Customer Satisfaction Consultants will need the following information to process the emergency order. It will be delivered between 10:00 a.m. and 2:00 p.m. the next day directly to the hospital pharmacy from our warehouse in Knoxville, TN and billed through their wholesaler.

• Customer name
• Address (Street, City, State and Zip code)
• Telephone #
• Contact name
• Purchase order #
• Order quantity (Argatroban single-dose vials NDC #0007-4407-01)
• Wholesaler name, city and state (For billing and drop ship approval)
Emergency orders must be called in to GSK Customer Satisfaction by 3:00 p.m. for next day delivery.
After normal business hours, weekends and holidays only, contact GSK at 1-800-366-8900.

IMPORTANT: You must use the above contact phone numbers for emergency information or availability and NOT the Contact Us form on this Web site.

Indications
Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.

Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).

Important Safety Information

As with all anticoagulants, bleeding is a serious concern. Argatroban is contraindicated in patients with overt major bleeding or those with hypersensitivity to the product or any of its components. Argatroban should be used with extreme caution in disease states or other circumstances in which there is an increased risk of hemorrhage. Overall major bleeding was reported in 5.3% of patients with HIT treated with Argatroban versus 6.7% of the historical controls. Overall major bleeding was reported in 1.8% of patients undergoing PCI treated with Argatroban versus 3.1% of the historical controls. Intracranial bleeding was not observed in the 568 patients treated with Argatroban for HIT (with or without thrombosis) or in the 91 patients who underwent PCI. The most common nonhemorrhagic side effects in HIT patients, regardless of the relationship to treatment, were dyspnea, hypotension, and fever. In patients undergoing PCI, the nonhemorrhagic side effects, regardless of the relationship to treatment, included chest pain, hypotension, and back pain. Please see full Prescribing Information for additional safety information on Argatroban.